Shire gets sector perform rating by RBC

RBC Capital Markets analyst Douglas Miehm gave Shire plc a sector perform, above average risk, rating on news the company's partner, New River Pharmaceuticals, Inc., received an approvable letter from the Food and Drug Administration for NRP104. The FDA requested no additional studies and is proposing Schedule II classification. RBC increased its target price to $57 from $53. Shares of the London-based specialty pharmaceutical company were up 65 cents, or 1.22%, at $53.75. (Nasdaq: SHPGY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.